American Portfolios Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

American Portfolios Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-300	Closed	-$18K	–	2931
2019 Q4	$18K	Hold	300	–	–	﹤0.01%	1767
2019 Q3	$17K	Hold	300	–	–	﹤0.01%	1728
2019 Q2	$16.7K	Hold	300	–	–	﹤0.01%	1724
2019 Q1	$15.1K	Hold	300	–	–	﹤0.01%	1678
2018 Q4	$12.1K	Hold	300	–	–	﹤0.01%	1550
2018 Q3	$20.8K	Hold	300	–	–	﹤0.01%	1472
2018 Q2	$22.7K	Hold	300	–	–	﹤0.01%	1413
2018 Q1	$15.8K	Hold	300	–	–	﹤0.01%	1465
2017 Q4	$16K	Buy	+300	New	+$16.7K	﹤0.01%	1404

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Portfolios Advisors's EGRX Position: Q1 2020 in Review

American Portfolios Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2020, closing a stake of 300 shares — an estimated $18K sold.

American Portfolios Advisors first reported a position in EGRX in Q4 2017 and held it in 9 quarters. The position peaked at $22.7K in Q2 2018. 168 funds tracked by Wall St. Rank hold EGRX as of Q1 2020.

American Portfolios Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
American Portfolios Advisors sold 300 Eagle Pharmaceuticals, Inc. shares in Q1 2020, an estimated $18K.
American Portfolios Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2017 and held it in 9 quarters.
American Portfolios Advisors's Eagle Pharmaceuticals, Inc. position peaked at $22.7K in Q2 2018.
168 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2020.

Based on American Portfolios Advisors's 13F filing for Q1 2020, filed 24 Mar 2023.